Ibrutinib for mantle cell lymphoma.
Plymouth, United Kingdom. In Future Oncol, 13 Feb 2016
Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor.
Mantle Cell Lymphoma.
Australia. In J Clin Oncol, 11 Feb 2016
In particular, agents recently approved by the Food and Drug Administration include the proteasome inhibitor bortezomib, immunomodulator lenalidomide, and Bruton's tyrosine kinase inhibitor ibrutinib.